KALY Evaluates Patented Cannabis Extract For Potential Coronavirus Treatment
Dallas, Tx – February 28, 2020 - Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today again confirmed efforts to evaluate its proprietary CBD extract formulation as a treatment for coronavirus symptoms. KALY’s proprietary CBD formulation has been developed for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s U.S. Patented Cannabis Extraction Process. In conjunction with a recently published research study (Journal of Cannabis Research) the CBD extract provides significant anti-inflammatory responses in vitro. The next phase of research is now moving forward in preclinical in vivo research to expand evaluation of the effects on lung function, total body distribution, whole body clearance of the extract and dosage evaluations for maximal efficacy. KALY has filed a new patent application specifically on its CBD formulation for symptoms associated with COPD and other similar respiratory conditions. KALY has also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions that result from respiratory inflammation.
NCM BIOTECH and the contract research organization Primates Plus Collaboration
NCM BIOTECH looks forward to working with Primates Plus to identify other major positive effects of NCMB-1 on significant diseases of lungs, kidneys and the cardiovascular system including hypertension, diabetes, heart and kidney disease.
The Journal of Cannabis Research to Publish Effects of Cannabis Oil Extract on COPD
The Journal of Cannabis Research to publish The "Effects of Cannabis Oil Extract on Immune Response Gene Expression in Human Small Airway Epithelial Cells (HSAEpC): Implications for Chronic Obstructive Pulmonary Disease (COPD)" manuscript. The manuscript was written in collaboration by Stephen Mamber, Volkan Gurel, Jeremy Lins, Frederick Ferri, Sarah Beseme and John McMichael.
NCM BIOTECH issued provisional Patent for COPD Treatment
NCM BIOTECH Founder and President, Frederick Ferri, is very pleased to announce that NCM BIOTECH has been issued a provisional Patent for their ground breaking COPD Treatment. Under United States patent law, a provisional application is a legal document filed in the United States Patent and Trademark Office. Fredd is excited to work toward an issued patent over the next year.
Please keep checking back on our Patent Status.
NCM BIOTECH expands into HEMP
NCM BIOTECH founder Frederick Ferri is excited to announce the creation of Natures CBD Americas, an extraction formulation company. The newly formed Natures CBD Americas will be Mr. Ferri’s move into the booming Hemp Markets. Mr. Ferri is planning on using NCM BIOTECH’s state of the art extraction formula for HEMP CBD retail production.
Fredd is confident that the move into the HEMP market has excellent synergies with his current work in the Cannabis market and will yield the same success.
NCM BIOTECH Founder Explores Hemp Expansion in North Carolina
October 25, 2019 NCM Biotech is pleased to announce our Founder Frederick Ferri met with Butterball’s Jim Maxwell and North Carolina 7th District Congressman David Rouzer to discuss the expansion of the hemp
industry in North Carolina.